Cannabinoids, Learning, and Memory

Phase 1Active Not RecruitingNCT02407808

Yale University80 enrolled

Overview

The overarching goal of this study is to characterize the effects of cannabinoids on working and episodic memory.

This study will be achieved by studying the acute effects of delta-9-tetrahydrocannabinol (THC), the main psychoactive component of cannabis and a cannabinoid-1 receptor (CB1R) agonist, on a wide range of memory tasks in healthy human subjects.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

QUADRUPLE

Enrollment

Conditions

Cannabis Psychotic Disorders

Interventions

THCDRUG

Active THC (0.0015-0.03 mg/kg) administered over 20 minutes.

PlaceboDRUG

Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 20 minutes.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Men and women aged 18 and 55 years (extremes included) on day of first dosing * Exposed to cannabis at least once in their lifetime Exclusion Criteria: * Cannabis naive * Positive pregnancy screen during screening * Hearing deficits

Locations (1)

VA Connecticut Healthcare System

West Haven, Connecticut, United States

Outcomes

Primary Outcomes

Rey Auditory Verbal Learning Test (RAVLT)

a measure of verbal episodic memory

Time frame: +35 minutes after infusion

N-Back Task

a measure of working memory

Time frame: +65 minutes after infusion

Secondary Outcomes

Clinician Administered Dissociative Symptoms Scale (Total Score)

Time frame: Baseline, +10, +85, and +240 minutes after the first infusion

Visual Analog Scale (Total Score)

a measure of THC intoxication

Time frame: Baseline, +10, +85, +240 minutes after the first infusion

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.